Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | RAD52 | P43351 | 5/20 | 1.00 |
| ▸ | KDM1A | O60341 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 1.00 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.89 |
| ▸ | RAC1 | P63000 | 2/20 | 0.89 |
| ▸ | ACHE | P22303 | 7/20 | 0.87 |
| ▸ | APP | P05067 | 1/20 | 0.87 |
| ▸ | MAOB | P27338 | 1/20 | 0.87 |
| ▸ | EP300 | Q09472 | 6/20 | 0.83 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.83 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.83 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Jatrorrhizine SCHEMBL29381269 | 1.00 | CYP3A4 (1.00) | CYP3A4MAPTRAD52KDM1ALMNA | |
| Jatrorrhizine SCHEMBL29368316 | 1.00 | CYP3A4 (1.00) | CYP3A4MAPTRAD52KDM1ALMNA | |
| Jatrorrhizine SCHEMBL1427435 | 0.99 | CYP3A4 (0.98) | CYP3A4MAPTRAD52KDM1ALMNA | |
| Jatrorrhizine SCHEMBL21809027 | 0.99 | CYP3A4 (0.98) | CYP3A4MAPTRAD52KDM1ALMNA | |
| Jatrorrhizine SCHEMBL31238510 | 0.99 | CYP3A4 (0.98) | CYP3A4MAPTRAD52KDM1ALMNA | |
| Columbamine SCHEMBL29395690 | 0.95 | CYP3A4 (1.00) | CYP3A4MAPTRAD52KDM1ALMNA | |
| Columbamine SCHEMBL422073 | 0.95 | CYP3A4 (1.00) | CYP3A4MAPTRAD52KDM1ALMNA | |
| Columbamine SCHEMBL3324164 | 0.94 | CYP3A4 (0.98) | CYP3A4MAPTRAD52KDM1ALMNA | |
| SCHEMBL2742479 | 0.94 | RAC1 (1.00) | CYP3A4MAPTRAD52KDM1ALMNA | |
| Hydrochloric Acid SCHEMBL3320114 | 0.93 | RAC1 (1.00) | CYP3A4MAPTRAD52KDM1ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1380 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4687856-A2 | GLP-1R AGONIST AND DPP-4 INHIBITOR COMPOSITIONS AND METHODS OF USING | JDS Therapeutics, LLC (US) | 2026-02-11 | — | — | EP | claimed |
| US-20250261667-A1 | BERBERINE ALKALOID FORMULATIONS IN THE PREVENTION AND/OR TREATMENT OF INFECTIOUS DISEASE | IRP Health Pty Ltd (AU) | 2025-08-21 | — | — | US | claimed |
| CN-120084909-A | Multi-component content determination method for four-ingredient Tibetan cat-milk soup | 青岛科技大学 | 2025-06-03 | — | — | CN | claimed |
| CN-120064481-A | Method for optimizing classical name square Xiaoqiao decoction extraction process based on orthogonal combination reference association degree and AHP-entropy weight method | 陕西省中医医院 | 2025-05-30 | — | — | CN | claimed |
| US-12295366-B2 | Preservation of personal care compositions | SHARON LABORATORIES LTD. (IL) | 2025-05-13 | — | — | US | claimed |
| CN-117427088-B | Equivalent component group of Angong bezoar bolus for improving ischemic cerebral apoplexy injury and application thereof | 中国药科大学 | 2025-05-09 | — | — | CN | claimed |
| CN-119699475-A | Use of berberine alkaloid in preventing and/or treating intestinal diseases | IRP健康股份有限公司 | 2025-03-28 | — | — | CN | claimed |
| WO-2025015679-A1 | BITTER FLAVORING AGENT FOR GEL | 成都中医药大学 | 2025-01-23 | — | — | WO | claimed |
| CN-119234839-A | Application of coptis chinensis water extract in preparation of biopesticide for inhibiting black spore mold | 南京中医药大学 | 2025-01-03 | — | — | CN | claimed |
| US-20250002490-A1 | BERBERINE SALTS, URSODEOXYCHOLIC SALTS AND COMBINATIONS, METHODS OF PREPARATION AND APPLICATION THEREOF | SHENZHEN HIGHTIDE BIOPHARMACEUTICAL LTD (CN) | 2025-01-02 | — | — | US | claimed |
| US-20070190187-A1 | FORMULATION FOR ENHANCED DELIVERY OF PHENETHYLAMINE | KNELLER BRUCE W | 2007-08-16 | — | — | US | claimed |
| US-20070116779-A1 | Comprehensive nutraceutical agent for treatment/ prevention of Parkinson's disease | MAZZIO ELIZABETH | 2007-05-24 | — | — | US | claimed |
| WO-2007029187-A2 | USE OF PROTOBERBERINES AS AN ACTIVE SUBSTANCE REGULATING THE PILOSEBACEOUS UNIT | SEDERMA (FR) | 2007-03-15 | — | — | WO | claimed |
| CN-1908298-A | Application of phellodendron bark in paper and paperboard making | HUANG HUAXIN (CN) | 2007-02-07 | — | — | CN | claimed |
| CN-1908084-A | Application of phellodendron in coating manufacture | HUANG HUAXIN (CN) | 2007-02-07 | — | — | CN | claimed |
| US-20040091556-A1 | Nasal irrigation solutions and methods of using same | TIGUNAIT RAJMANI (US) | 2004-05-13 | — | — | US | claimed |
| WO-2004011017-A1 | NASAL IRRIGATION SOLUTIONS AND METHODS OF USING SAME | HIMALAYAN INTERNATIONAL INSTITUTE OF YOGA SCIENCE AND PHILOSOPHY (US) | 2004-02-05 | — | — | WO | claimed |
| US-6280768-B1 | ADMINISTERING BERBERINE ALKALOID, AND CONTINUING ADMINISTRATION FOR SUFFICIENT TIME TO ALLEVIATE CHRONIC DIARRHEA INDUCED BY PROTOZOA SELECTED FROM GROUP CONSISTING PROTOZOA SELECTED FROM MICROSPORRIDIA AND CRYPTOSPORDIA SPP. | PRM PHARMACEUTICALS, INC. | 2001-08-28 | — | — | US | claimed |
| CN-1189365-A | Medicine for preventing Aids virus, treponema pallidum, neisseria gonorrhoeae and trichomonad | LEI XUEJUN (CN) | 1998-08-05 | — | — | CN | claimed |
| WO-1998000018-A1 | BERBERINE ALKALOIDS AS A TREATMENT FOR CHRONIC, PROTOZOALLY-INDUCED DIARRHEA | PRM PHARMACEUTICALS, INC. (US) | 1998-01-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070190187-A1 | FORMULATION FOR ENHANCED DELIVERY OF PHENETHYLAMINE | MAOB, PNMT, MAOA | CYP3A4 11/4885MAPT 535/4885RAD52 4094/4885 |
| US-20250002490-A1 | BERBERINE SALTS, URSODEOXYCHOLIC SALTS AND COMBINATIONS, METHODS OF PREPARATION AND APPLICATION THEREOF | CYP27A1, NR1H4, CYP7A1 | CYP3A4 213/4885MAPT 1349/4885RAD52 4004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.